RGEN News and Press, Repligen Corporation From 09/04/22

The biotech industry is heavily regulated by the federal government and its science watchdog, the Food and Drug Administration (FDA). As a consequence, biotech investors often evaluate a possible investment by looking at the company's pipeline of future assets. Research and development is a...

Summary Bruker Corporation has done alright from an operational perspective, with sales continuing to rise modestly this year. Foreign currency is an issue right now and profits have contracted, posing investors some risk. Although shares are getting cheaper, they do still loo...

WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator of bioprocessing technologies and solutions, today announced that it will host “Repligen Investor Day 2022” on Tuesday, September 20. The live event will take place at the...

Update 4:40pm : Adds Repligen declining to comment. Repligen ( NASDAQ: RGEN ) briefly went positive after a report that the biotech firm rejected an unsolicited bid from Catalent ( NYSE: CTLT ). Repligen ( RGEN ) is said to have hired advisers for a tak...

Repligen ( NASDAQ: RGEN ) briefly went positive after a report that the biotech firm rejected an unsolicited bid from Catalent ( NYSE: CTLT ). Repligen ( RGEN ) is said to have hired advisers for a takeover dense after reviewing the Catalent ( CTLT ) offer ...

Shares in bioprocessing equipment company Repligen (NASDAQ: RGEN) soared by more than 14% this week by late Thursday. The move comes after an excellent set of second-quarter earnings released on Tuesday. The results were ahead of expectations, and management increased its full-year ...

Shares of the bioprocessing giant Repligen Corporation (NASDAQ: RGEN) are glowing green today. Specifically, the biotech's stock was up by as much as 14.9% earlier today. Repligen's shares have cooled off slightly since hitting this high water mark early on in Tuesday's session. But...

Repligen Corporation (RGEN) Q2 2022 Earnings Conference Call August 02, 2022 8:30 AM ET Company Participants Sondra Newman – Head-Investor Relations Tony Hunt – President and Chief Executive Officer Jon Snodgres – Chief Financial Officer ...

A boost in fiscal 2022 revenue and earnings guidance from previous guidance has led Repligen ( NASDAQ: RGEN ) to rise 11% in Tuesday morning trading. The biological drugs components company also beat on the top and bottom lines in its Q2 2022 results. Non-GAAP ...

Repligen press release ( NASDAQ: RGEN ): Q2 Non-GAAP EPS of $0.91 beats by $0.20 . Revenue of $207.63M (+27.4% Y/Y) beats by $18.57M . FY2022 outlook : Total revenue is expected to be in the range of $790M-$810M, an increase from previous guidance of $770M-...